New Beta-Lactamase Inhibitors Research and Development: Sword for Antimicrobial Resistance
A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "The Global Need for Effective Antibiotics".
Deadline for manuscript submissions: 20 August 2024 | Viewed by 688
Special Issue Editor
Interests: antimicrobial resistance; novel antimicrobial agents; β-lactamases; MDR Gram-negative infections; rapid diagnostics; precision antimicrobial chemotherapy
Special Issue Information
Dear Colleagues,
The evolution and spread of β-lactamases in Gram-negative bacteria present challenges in the treatment of many infections for which β-lactams (penicillins, cephalosporins, carbapenems) are employed. The combination of a β-lactam (BL) with a β-lactamase inhibitor (BLI) is a proven strategy to address this problem. In recent years, there have been efforts to design novel BLIs (diazobicyclooctanes, boronic acids) and to repurpose older drugs (clavulanate, tazobactam, sulbactam) in novel therapeutic combinations.
Although a number of new BL/BLI preparations are entering clinical application (ceftazidime/avibactam, ceftolozone/tazobactam, imipenem/relebactam, meropenem/vaborbactam), these are already compromised by the emergence of resistance. Most also lack useful activity against key MDR pathogens (Acinetobacter, Pseudomonas) and do not inhibit the metallo-β-lactamases (NDM, IMP, VIM) responsible for carbapenem resistance.
In this Special Issue, we seek manuscripts that review or provide insights into the development or repurposing of novel or existing BL/BLI combination therapies. This may include articles on chemical and biochemical activity, the mechanisms of genotypic and phenotypic resistance, regional epidemiological surveillance studies, in vitro susceptibility testing and diagnostics, PK/PD analyses and dosing strategies, clinical outcome studies and case reports.
Dr. David Wareham
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antimicrobials
- β-lactams
- β-lactamase inhibitors
- antimicrobial resistance
- epidemiology
- surveillance
- antimicrobial chemotherapy
- gram-negative infections
